LATEST TRIALS

  • Solide Tumores
    An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • Solide Tumores
    Safety and tolerability of single and repeated doses of ODM-203: an opel-label, non-randomized, uncontrolled, dose escalation, multicentre, first-in-human study in subjects with advanced solid tumors
  • Solide Tumores
    An Open-label Non-randomised Multicentre Comparative Phase I Studyof the Pharmacokinetics Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients with Advanced Solid Tumours and Normal Renal Function or Renal Impairment

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen